CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan

Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies

(2023) Michel van den Heuvel et al.   TUMOR BIOLOGY

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

(2022) Priyanka Gaitonde et al.   Cancer Management and Research

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review

(2021) Josefien W. Hommes et al.   Frontiers in Oncology

P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease

(2021) A. Mang et al.   Journal of Thoracic Oncology

Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy

(2020) Maxime Frelaut et al.   BIODRUGS

Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review

(2019) Shemana Cassim et al.   BMC CANCER

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

(2019) Lucas Goldfarb et al.   EJNMMI Research

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

(2019) Guillaume Herbreteau et al.   Journal of Thoracic Disease

Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer

(2019) Akihiro Yoshimura et al.   Translational Lung Cancer Research

Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting

(2019) Jason C Simeone et al.   Future Oncology

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

(2018) M. Tazdait et al.   EUROPEAN JOURNAL OF CANCER

The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)

(2018) Thomas Muley et al.   LUNG CANCER

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

(2018) Yingming Zhu et al.   Cancer Management and Research

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

(2017) Katja Pinker et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Progress and prospects of early detection in lung cancer

(2017) Sean Blandin Knight et al.   Open Biology

The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

(2017) Linjie Liu et al.   Biomed Research International

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

(2015) Ai-Gui Jiang et al.   BMC CANCER

Inter-observer reproducibility of semi-automatic tumor diameter measurement and volumetric analysis in patients with lung cancer

(2013) J. Dinkel et al.   LUNG CANCER

Intra- and Interobserver Variability in CT Measurements in Oncology

(2013) Aoife McErlean et al.   RADIOLOGY

Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes

(2011) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

(2010) Ho Yun Lee et al.   LUNG CANCER

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER